USPTO serial 97792209
HELIX BIOTECH
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- BELL, MARLENE D
- Law office
- TMO LAW OFFICE 118
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with HELIX BIOTECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Knoxville, TN, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Wade R. Orr
Wade R. Orr Luedeka Neely, P.C.P.O. Box 1871Knoxville, TN 37901United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Chemical analysis; Chemical analysis services; Chemical research and analysis; Chemical, biochemical, biological and bacteriological research and analysis; Clinical research in the field of Lipid Nanoparticles, Liposomes, and Hybrid Nanoparticles; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Product development; Product development and engineering services for others; Product development consultation; Product development consulting in the field of Lipid Nanoparticles (LNPs) and Liposome Samples. LNP and Liposome Formulation, Manufacturing, and Analytical Services; Product development for others; Product research and development; Basic and clinical research in the field of respiratory science and medicine; Consulting services for others in the field of design, planning, and implementation project management of Lipid Nanoparticles, Liposomes, and Hybrid Nanoparticles; Consulting services in the field of product design and development; Design and testing for new product development; Executing of chemical analyses; Medical and scientific research, namely, conducting clinical trials for others; Performance of chemical analyses; Providing a web site featuring technology enabling physicians to access resources in clinical medicine; Providing a website featuring educational information in the field of clinical research; Providing information on clinical studies via an interactive website; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing reagent sample testing and diagnostic services for others for scientific research purposes; Scientific research in the nature of conducting clinical trials for others; Scientific research in the nature of conducting clinical trials for others in the field of Lipid Nanoparticles, Liposomes, and Hybrid Nanoparticles; Testing, analysis and evaluation of leaf and petiole samples; Working on and evaluation of chemical analyses | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 23, 2026 | MAB1 | ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT | — |
| Jul 23, 2026 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Jul 22, 2026 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| May 23, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 20, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 19, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 18, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 24, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 15, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 15, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 15, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 12, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 12, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 12, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 8, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 8, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 8, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 15, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 15, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 10, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 3, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Mar 2, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 16, 2023 | NWAP | NEW APPLICATION ENTERED | — |